• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by PolyPid Ltd.

    10/28/24 4:01:03 PM ET
    $PYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PYPD alert in real time by email
    SC 13G/A 1 ea0217289-13ga1cent_polypid.htm AMENDMENT NO. 1 TO SCHEDULE 13G

     

     

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

     

    SCHEDULE 13G/A

     

    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO § 240.13d-2

     

    (Amendment No. 1)*

     

    PolyPid Ltd.

     

    (Name of Issuer)

     

    Ordinary Shares, no par value

     

    (Title of Class of Securities)

     

    M8001Q126

     

    (CUSIP Number)

     

    Rodney Hodges

    Director
    c/o Geneva Trust Company (GTC) SA, Rue de l’Athénée 34

    1206 Genève, Switzerland
    Tel +41 22 789 1200

     

    (Name, Address and Telephone Number of Person
    Authorized to Receive Notices and Communications)

     

    September 30, 2024

     

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      ☐ Rule 13d-1(b)

     

      ☒ Rule 13d-1(c)

     

      ☐ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (the “Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. M8001Q126 13G/A Page 2 of 13 Pages
    1. NAMES OF REPORTING PERSON

    Rodney Hodges
    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (See Instructions)

    (a) ☐

    (b) ☐

    3. SEC USE ONLY
     
    4. CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United Kingdom
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5.

    SOLE VOTING POWER
     

    0

    6. SHARED VOTING POWER
     
    632,431
    7.

    SOLE DISPOSITIVE POWER
     

    0

    8. SHARED DISPOSITIVE POWER
     
    632,431
    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    632,431

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)    

    ☐

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    9.3%(1)

    12. TYPE OF REPORTING PERSON (see instructions)

    IN

     

    (1)Percentage is based on the 6,803,478 Ordinary Shares of the Issuer that were outstanding as of August 27, 2024, based on information contained in the Form F-3 filed by the Issuer on August 30, 2024.

     

     

     

     

    CUSIP No. M8001Q126 13G/A Page 3 of 13 Pages
    1. NAMES OF REPORTING PERSON

    POD Sàrl
    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (See Instructions)

    (a) ☐

    (b) ☐

    3. SEC USE ONLY
     
    4. CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Switzerland
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5. SOLE VOTING POWER
     
    0
    6.

    SHARED VOTING POWER
     

    632,431

    7. SOLE DISPOSITIVE POWER
     
    0
    8.

    SHARED DISPOSITIVE POWER
     

    632,431

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    632,431

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)    

    ☐

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    9.3%(1)

    12. TYPE OF REPORTING PERSON (see instructions)

    CO

     

    (1)Percentage is based on the 6,803,478 Ordinary Shares of the Issuer that were outstanding as of August 27, 2024, based on information contained in the Form F-3 filed by the Issuer on August 30, 2024.

     

     

     

     

    CUSIP No. M8001Q126 13G/A Page 4 of 13 Pages
    1. NAMES OF REPORTING PERSON

    Geneva Holding Company (GHC) SA
    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (See Instructions)

    (a) ☐

    (b) ☐

    3. SEC USE ONLY
     
    4. CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Switzerland

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5. SOLE VOTING POWER
     
    0
    6.

    SHARED VOTING POWER
     

    632,431

    7. SOLE DISPOSITIVE POWER
     
    0
    8.

    SHARED DISPOSITIVE POWER
     

    632,431

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    632,431

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)    

    ☐

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    9.3%(1)

    12. TYPE OF REPORTING PERSON (see instructions)

    HC

     

    (1)Percentage is based on the 6,803,478 Ordinary Shares of the Issuer that were outstanding as of August 27, 2024, based on information contained in the Form F-3 filed by the Issuer on August 30, 2024.

     

     

     

     

    CUSIP No. M8001Q126 13G/A Page 5 of 13 Pages
    1. NAMES OF REPORTING PERSON

    Geneva Trust Company (GTC) SA
    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (See Instructions)

    (a) ☐

    (b) ☐

    3. SEC USE ONLY
     
    4. CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Switzerland
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5. SOLE VOTING POWER
     
    0
    6.

    SHARED VOTING POWER
     

    632,431

    7. SOLE DISPOSITIVE POWER
     
    0
    8.

    SHARED DISPOSITIVE POWER
     

    632,431

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    632,431

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)    

    ☐

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    9.3%(1)

    12. TYPE OF REPORTING PERSON (see instructions)

    HC

     

    (1)Percentage is based on the 6,803,478 Ordinary Shares of the Issuer that were outstanding as of August 27, 2024, based on information contained in the Form F-3 filed by the Issuer on August 30, 2024.

     

     

     

     

    CUSIP No. M8001Q126 13G/A Page 6 of 13 Pages
    1. NAMES OF REPORTING PERSON

    Centaurus Investments Limited
    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (See Instructions)

    (a) ☐

    (b) ☐

    3. SEC USE ONLY
     
    4. CITIZENSHIP OR PLACE OF ORGANIZATION
     
    British Virgin Islands
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5. SOLE VOTING POWER
     
    0
    6.

    SHARED VOTING POWER
     

     609,642

    7. SOLE DISPOSITIVE POWER
     
    0
    8.

    SHARED DISPOSITIVE POWER
     

     609,642

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     609,642

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)    

    ☐

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    9.0%(1)

    12. TYPE OF REPORTING PERSON (see instructions)

    HC

     

    (1)Percentage is based on the 6,803,478 Ordinary Shares of the Issuer that were outstanding as of August 27, 2024, based on information contained in the Form F-3 filed by the Issuer on August 30, 2024.

     

     

     

     

    CUSIP No. M8001Q126 13G/A Page 7 of 13 Pages
    1. NAMES OF REPORTING PERSON

    Xenia Venture Capital Limited
    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (See Instructions)

    (a) ☐

    (b) ☐

    3. SEC USE ONLY
     
    4. CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Israel
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5. SOLE VOTING POWER
     
    0
    6.

    SHARED VOTING POWER
     

    540,468

    7. SOLE DISPOSITIVE POWER
     
    0
    8.

    SHARED DISPOSITIVE POWER
     

    540,468

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    540,468

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions) 

    ☐

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    7.9%(1)

    12. TYPE OF REPORTING PERSON (see instructions)

    HC

     

    (1)Percentage is based on the 6,803,478 Ordinary Shares of the Issuer that were outstanding as of August 27, 2024, based on information contained in the Form F-3 filed by the Issuer on August 30, 2024.

     

     

     

     

    CUSIP No. M8001Q126 13G/A Page 8 of 13 Pages

     

    Item 1.

     

    (a)

    Name of Issuer

    PolyPid Ltd. (the “Issuer”)

       
    (b)

    Address of Issuer’s Principal Executive Offices
    18 Hasivim Street

    Petach Tikva 495376, Israel

     

    Item 2.

     

    (a)

    Name of Person Filing:

     

    This Statement of Beneficial Ownership on Schedule 13G, filed on October 28, 2024 (the “Statement”) is being filed by each of:

     

    (i)  Xenia Venture Capital Limited;

     

    (ii)  Centaurus Investments Limited;

     

    (iii) Geneva Holding Company (GHC) SA;

     

    (iv) Geneva Trust Company (GTC) SA;

     

    (v)  POD Sàrl (all of which, above, are the “Reporting Entities”); and

     

    (vi) Rodney Hodges (the “Reporting Individual”),

     

    (each a “Reporting Person” and, collectively, the “Reporting Persons”). This Schedule 13G is being filed pursuant to a Joint Filing Agreement (the “Joint Filing Agreement”), a copy of which was filed as Exhibit 99.1 to the Schedule 13G filed on September 20, 2023.

     

    Xenia Venture Capital Limited (“Xenia”) is an investment holding company that purchased Ordinary Shares (as defined below) of the Issuer that are the subject of this Statement of Beneficial Ownership on Schedule 13G. The entire share capital of Centaurus Investments Limited, the parent holding company of Xenia, is held by Geneva Trust Company (GTC) SA (as trustee of the VT Two Trust). Geneva Trust Company (GTC) SA (a subsidiary of Geneva Holding Company (GHC) SA), as trustee of VT Two Trust, has the authority to dispose of and exercise control over the disposal of the assets of the VT Two Trust. POD Sàrl, of which Mr. Rodney Hodges holds 100% of the share capital, wholly owns Geneva Holding Company (GHC) SA.

     

    The Reporting Individual does not make day-to-day voting or investment decisions with respect to the Ordinary Shares held by the Reporting Entities and therefore disclaims beneficial ownership of them except to the extent of his pecuniary interest therein.

       
    (b)

    Address of Principal Business Office or, if None, Residence:

     

    The principal business office of each of the Reporting Persons are:

     

    Rodney Hodges, Rue de l’Athénée 34, 1206 Genève, Switzerland 

    POD Sàrl, Rue de l’Athénée 34, 1206 Genève, Switzerland 

    Geneva Holding Company (GHC) SA, Rue de l’Athénée 34, 1206 Genève, Switzerland 

    Geneva Trust Company (GTC) SA, Rue de l’Athénée 34, 1206 Genève, Switzerland 

    Centaurus Investments Limited, Rue de l’Athénée 34, 1206 Genève, Switzerland 

    Xenia Venture Capital Limited, Yigal Alon 76, 6706701 Tel Aviv, Israel

       
    (c)

    Citizenship:


    POD Sàrl, Geneva Holding Company (GHC) SA, and Geneva Trust Company (GTC) SA are organized under the laws of Switzerland, Centaurus Investments Limited is organized under the laws of British Virgin Islands, and Xenia Venture Capital Limited is organized under the laws of Israel. The Reporting Individual is a citizen of the United Kingdom.

       
    (d) Title of Class of Securities
    Ordinary shares, no par value per share (“Ordinary Shares”)
       
    (e) CUSIP Number
    M8001Q126

     

     

     

     

    CUSIP No. M8001Q126 13G/A Page 9 of 13 Pages

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a) ☐ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
         
    (b) ☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
         
    (c) ☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
         
    (d) ☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
         
    (e) ☐ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
         
    (f) ☐ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
         
    (g) ☐ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
         
    (h) ☐ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
         
    (i) ☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
         
    (j) ☐ A non-U.S. institution in accordance with § 240.13d–1(b)(1)(ii)(J);
         
    (k) ☐ Group, in accordance with §240.13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with § 240.13d–1(b)(1)(ii)(J), please specify the type of institution: ________

     

    Not applicable.

     

    Item 4. Ownership.

     

    (a) (b) Number and percentage of Issuer Ordinary Shares beneficially owned by each Reporting Person:

     

    Reporting Person  Number of
    Ordinary
    Shares
       Percentage
    of Class
     
    Rodney Hodges   632,431    9.3%
    POD Sàrl   632,431    9.3%
    Geneva Holding Company (GHC) SA   632,431    9.3%
    Geneva Trust Company (GTC) SA   632,431    9.3%
    Centaurus Investments Limited   609,642    9.0%
    Xenia Venture Capital Limited   540,468    7.9%

     

     

     

     

    CUSIP No. M8001Q126 13G/A Page 10 of 13 Pages

     

    With respect to each of the Reporting Persons:

     

    (a) Number of shares as to which the Reporting Person has:
         
      (i)

    Sole power to vote or to direct the vote: 

    Rodney Hodges: 0

    POD Sàrl: 0

    Geneva Holding Company (GHC) SA: 0

    Geneva Trust Company (GTC) SA: 0

    Centaurus Investments Limited: 0

    Xenia Venture Capital Limited: 0

     

      (ii)

    Shared power to vote or to direct the vote: 

    Rodney Hodges: 632,431

    POD Sàrl: 632,431

    Geneva Holding Company (GHC) SA: 632,431

    Geneva Trust Company (GTC) SA: 632,431

    Centaurus Investments Limited: 609,642

    Xenia Venture Capital Limited: 540,468

         
      (iii)

    Sole power to dispose or to direct the disposition of: 

    Rodney Hodges: 0

    POD Sàrl: 0

    Geneva Holding Company (GHC) SA: 0

    Geneva Trust Company (GTC) SA: 0

    Centaurus Investments Limited: 0

    Xenia Venture Capital Limited: 0

         
      (iv)

    Shared power to dispose or to direct the disposition of: 

    Rodney Hodges: 632,431

    POD Sàrl: 632,431

    Geneva Holding Company (GHC) SA: 632,431

    Geneva Trust Company (GTC) SA: 632,431

    Centaurus Investments Limited: 609,642

    Xenia Venture Capital Limited: 540,468

     

    Based on the Form F-3 filed by the Issuer on August 30, 2024, there were 6,803,478 Ordinary Shares of the Issuer outstanding as of August 27, 2024.

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

    Not applicable.

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person. 

     

    Not applicable.

     

     

     

     

    CUSIP No. M8001Q126 13G/A Page 11 of 13 Pages

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. 

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9. Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10. Certification.

     

    Each of the Reporting Persons hereby certifies as follows:

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the Issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     

     

     

    CUSIP No. M8001Q126 13G/A Page 12 of 13 Pages

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    RODNEY HODGES   POD SÀRL
             
    By: /s/ Rodney Hodges   By: /s/ Rodney Hodges
    Name:  Rodney Hodges   Name:  Rodney Hodges
    Date: October 28, 2024   Title: Authorized Signatory
          Date: October 28, 2024

     

    GENEVA HOLDING COMPANY (GHC) SA   XENIA VENTURE CAPITAL LIMITED
         
    By: /s/ Rodney Hodges   By: /s/ Eli Sorzon
    Name:  Rodney Hodges   Name:  Eli Sorzon
    Title: Authorized Signatory   Title: Authorized Signatory
    Date: October 28, 2024   Date: October 28, 2024

     

    By: /s/ Tobias Reinmann      
    Name: Tobias Reinmann      
    Title: Authorized Signatory      
    Date: October 28, 2024      

      

    GENEVA TRUST COMPANY (GTC) SA  
       
    By: /s/ Rodney Hodges  
    Name: Rodney Hodges  
    Title: Authorized Signatory  
    Date: October 28, 2024  
       
    By: /s/ Tobias Reinmann  
    Name: Tobias Reinmann  
    Title: Authorized Signatory  
    Date: October 28, 2024  
       
    CENTAURUS INVESTMENTS LIMITED  
       
    By: /s/ Rodney Hodges  
    Name:  Rodney Hodges  
    Title: Authorized Signatory for and on behalf of Champel Directors Limited  
    Date: October 28, 2024  
         
    By: /s/ Tobias Reinmann  
    Name: Tobias Reinmann  
    Title: Authorized Signatory for and on behalf of Florissant Global Limited  
    Date: October 28, 2024  

     

     

     

     

    CUSIP No. M8001Q126 13G/A Page 13 of 13 Pages

     

    EXHIBIT INDEX

     

    99.1  Joint Filing Agreement, dated September 20, 2023, among Rodney Hodges, Geneva Holding Company (GHC) SA, Geneva Trust Company (GTC) SA, Centaurus Investments Limited, POD Sàrl and Xenia Capital Limited (incorporated by reference to Exhibit 99.1 to the Schedule 13G filed Centaurus Investments Limited by on September 20, 2023).

     

     

     
    Get the next $PYPD alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $PYPD

    DatePrice TargetRatingAnalyst
    6/5/2025$9.00Buy
    Roth Capital
    6/2/2025$11.00Buy
    H.C. Wainwright
    1/28/2025$13.00Buy
    Rodman & Renshaw
    2/11/2022$23.00 → $17.00Strong Buy
    Raymond James
    9/14/2021$14.00Market Outperform
    JMP Securities
    7/30/2021$24.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $PYPD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Roth Capital initiated coverage on PolyPid Ltd. with a new price target

      Roth Capital initiated coverage of PolyPid Ltd. with a rating of Buy and set a new price target of $9.00

      6/5/25 7:35:43 AM ET
      $PYPD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright resumed coverage on PolyPid Ltd. with a new price target

      H.C. Wainwright resumed coverage of PolyPid Ltd. with a rating of Buy and set a new price target of $11.00

      6/2/25 8:53:56 AM ET
      $PYPD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rodman & Renshaw initiated coverage on PolyPid Ltd. with a new price target

      Rodman & Renshaw initiated coverage of PolyPid Ltd. with a rating of Buy and set a new price target of $13.00

      1/28/25 7:16:12 AM ET
      $PYPD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PYPD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • PolyPid Secures $26.7 Million Through Warrant Exercise Following Successful SHIELD II Phase 3 Trial Results

      The Company Anticipates that with this Additional Funding, PolyPid's Runway would be Extended beyond Anticipated U.S. Food and Drug Administration ("FDA") Approval of D-PLEX₁₀₀.The Company Recently Announced Successful Topline Results from its Phase 3 SHIELD II Trial; D-PLEX₁₀₀ Demonstrated a Statistically Significant Reduction in Surgical Site Infections ("SSIs") and Successfully Met the Study's Primary Endpoint and all Key Secondary Endpoints. PETACH TIKVA, Israel, June 17, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that following its recently announced successful S

      6/16/25 7:20:36 PM ET
      $PYPD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BriefCast Publishes Transcript: PolyPid Ltd. SHIELD II Phase 3 Trial Topline Results Call Transcript

      In a call hosted today, June 9, 2025, PolyPid Ltd. unveiled highly successful topline results from its SHIELD II Phase 3 trial of D-PLEX100 for preventing surgical site infections (SSIs) in abdominal colorectal surgery patients with large incisions. The double-blind trial of 798 patients achieved statistical significance across all endpoints, demonstrating a 38% reduction in the primary composite endpoint and a remarkable 58% reduction in SSI rates from 9.5% to 3.8% compared to standard care alone. These results position D-PLEX100 among the most effective prophylactic interventions for this indication, addressing a significant unmet medical need that costs the U.S. healthcare system up t

      6/9/25 8:54:32 AM ET
      $PYPD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PolyPid Announces Positive Topline Results from Phase 3 SHIELD II Trial: D-PLEX₁₀₀ Demonstrated Significant Reduction in Surgical Site Infections and Successfully Met Primary and All Key Secondary Endpoints

      D-PLEX100 successfully met the primary efficacy endpoint, with statistically significant results (p<0.005) in 798 patients with large abdominal surgery incisions.The trial successfully met all key secondary efficacy endpoints, including a 58% reduction in the rate of surgical site infections ("SSI") in patients treated with D-PLEX100 arm versus standard of care ("SoC") arm (p<0.005).The Company expects to submit a New Drug Application ("NDA") to the U.S. Food and Drug Administration ("FDA") in early 2026, with a Marketing Authorization Application ("MAA") in the E.U. to follow shortly thereafter.PolyPid will conduct a conference call and webcast at 8:30 A.M. ET today. PETACH TIKVA, Israel,

      6/9/25 7:30:00 AM ET
      $PYPD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PYPD
    SEC Filings

    See more
    • SEC Form 6-K filed by PolyPid Ltd.

      6-K - PolyPid Ltd. (0001611842) (Filer)

      6/25/25 4:05:12 PM ET
      $PYPD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form D filed by PolyPid Ltd.

      D - PolyPid Ltd. (0001611842) (Filer)

      6/23/25 4:05:15 PM ET
      $PYPD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by PolyPid Ltd.

      6-K - PolyPid Ltd. (0001611842) (Filer)

      6/17/25 8:38:44 AM ET
      $PYPD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PYPD
    Leadership Updates

    Live Leadership Updates

    See more
    • PolyPid Announces the Addition of Dr. Nurit Tweezer-Zaks to its Board of Directors

      PETACH TIKVA, Israel, Nov. 07, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced the appointment of Nurit Tweezer-Zaks, M.D., M.B.A, to its Board of Directors, effective November 6, 2023, following the retirement of Anat Tsour Segal. Dr. Tweezer-Zaks is a biopharmaceutical industry veteran with extensive executive business development, clinical, and R&D expertise. She is an experienced sector investor and was a practicing physician for nearly 15 years. "We are thrilled to welcome Dr. Tweezer-Zaks to the PolyPid Board. She has had a distinguished career as a practicing physic

      11/7/23 7:00:00 AM ET
      $PYPD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PolyPid Appoints UCSF Brain Tumor Center Director Mitchel S. Berger, M.D., to Oncology Advisory Board

      Dr. Berger Brings Extensive Expertise in Deep Brain Tumor Treatment The Company Expects to Initiate a Phase 1/2 Clinical Trial of OncoPLEX for Brain Tumors by the end of 2022 PETAH TIKVA, Israel, Jan. 04, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a phase 3 biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release therapeutics using its proprietary PLEX technology, today announced the appointment of Mitchel S. Berger, M.D., to its Oncology Advisory Board. Dr. Berger is the Berthold and Belle N. Guggenhime Professor of the Department of Neurological Surgery at the University of California, San Francisco (U

      1/4/22 7:30:00 AM ET
      $PYPD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PolyPid Announces Planned CEO Transition

      PETAH TIKVA, Israel, Jan. 03, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a Phase 3 biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release therapeutics using its proprietary PLEX technology, today announced that its Board of Directors has appointed Dikla Czaczkes Akselbrad, currently the Company's Executive Vice President and Chief Financial Officer, as PolyPid's Chief Executive Officer, effective July 1, 2022. Amir Weisberg, who currently serves as Chief Executive Officer and a director, will direct a transition period with Ms. Czaczkes Akselbrad beginning on April 1, 2022, and will retire from the Chief

      1/3/22 7:30:00 AM ET
      $PYPD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PYPD
    Financials

    Live finance-specific insights

    See more
    • BriefCast Publishes Transcript: PolyPid Ltd. SHIELD II Phase 3 Trial Topline Results Call Transcript

      In a call hosted today, June 9, 2025, PolyPid Ltd. unveiled highly successful topline results from its SHIELD II Phase 3 trial of D-PLEX100 for preventing surgical site infections (SSIs) in abdominal colorectal surgery patients with large incisions. The double-blind trial of 798 patients achieved statistical significance across all endpoints, demonstrating a 38% reduction in the primary composite endpoint and a remarkable 58% reduction in SSI rates from 9.5% to 3.8% compared to standard care alone. These results position D-PLEX100 among the most effective prophylactic interventions for this indication, addressing a significant unmet medical need that costs the U.S. healthcare system up t

      6/9/25 8:54:32 AM ET
      $PYPD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PolyPid Announces Positive Topline Results from Phase 3 SHIELD II Trial: D-PLEX₁₀₀ Demonstrated Significant Reduction in Surgical Site Infections and Successfully Met Primary and All Key Secondary Endpoints

      D-PLEX100 successfully met the primary efficacy endpoint, with statistically significant results (p<0.005) in 798 patients with large abdominal surgery incisions.The trial successfully met all key secondary efficacy endpoints, including a 58% reduction in the rate of surgical site infections ("SSI") in patients treated with D-PLEX100 arm versus standard of care ("SoC") arm (p<0.005).The Company expects to submit a New Drug Application ("NDA") to the U.S. Food and Drug Administration ("FDA") in early 2026, with a Marketing Authorization Application ("MAA") in the E.U. to follow shortly thereafter.PolyPid will conduct a conference call and webcast at 8:30 A.M. ET today. PETACH TIKVA, Israel,

      6/9/25 7:30:00 AM ET
      $PYPD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PolyPid to Host Conference Call and Webcast to Discuss D-PLEX₁₀₀ SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025

      PETACH TIKVA, Israel, June 06, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD), ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will host a conference call and webcast to report topline data for the SHIELD II Phase 3 trial, evaluating D-PLEX100 for the prevention of surgical site infections in patients undergoing abdominal colorectal surgery, on Monday, June 9, at 8:30 a.m. ET. To ensure you are connected prior to the beginning of the call, PolyPid suggests registering a minimum of 5 minutes before the start of the call. Conference Call Dial-In & Webcast Information: Date: Monday, June 9, 2025Time:8:30 AM Easte

      6/6/25 4:05:00 PM ET
      $PYPD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PYPD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by PolyPid Ltd.

      SC 13G/A - PolyPid Ltd. (0001611842) (Subject)

      12/12/24 7:05:07 AM ET
      $PYPD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by PolyPid Ltd.

      SC 13G/A - PolyPid Ltd. (0001611842) (Subject)

      11/29/24 1:20:33 PM ET
      $PYPD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by PolyPid Ltd.

      SC 13G/A - PolyPid Ltd. (0001611842) (Subject)

      10/28/24 4:01:03 PM ET
      $PYPD
      Biotechnology: Pharmaceutical Preparations
      Health Care